?:authorAffiliation
|
-
[\'Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France; Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.\', \'Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France.\', \'Anesthesia and Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Medical Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France.\', \'Department of Medical Oncology, Biotechnology and Immuno-Oncology Platform, University Hospital of Besançon, F-25000 Besançon, France.\', \'INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Chest Disease, University Hospital of Besançon, F-25000 Besançon, France.\', \'Anesthesia and Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3920, Université de Franche Comté, F-25000 Besançon, France.\', \'Medical Intensive Care Unit, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3920, Université de Franche Comté, F-25000 Besançon, France; Australian and New Zealand Intensive Care Research Center, Department of Epidemiology and Preventive Medicine, Monash University, Australia.\', \'Department of Virology, University Hospital of Besançon, F-25000 Besançon, France; Research Unit EA3181, Université de Franche Comté, F-25000 Besançon, France.\', \'INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France; Department of Medical Oncology, University Hospital of Besançon, F-25000 Besançon, France.\', \'Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France.\', \'Department of Pharmacy, University Hospital of Besançon, F-25000 Besançon, France; INSERM, EFS BFC, UMR1098, RIGHT, University of Bourgogne Franche-Comté, Interactions Greffon-Hôte-Tumeur/Ingénierie Cellulaire et Génique, F-25000 Besançon, France.\', \'Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France.\', \'Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000 Besançon, France.\', \'Department of Infectious Disease, University Hospital of Besançon, F-25000 Besançon, France; UMR-CNRS 6249 Chrono-Environnement, Université Bourgogne Franche-Comté, F-25000 Besançon, France. Electronic address: kbouiller@chu-besancon.fr.\']
|